Drug intelligence / Profile preview

Brixelle-Shine

Development stage: Preclinical
Lead developer: Bilix
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous, Subcutaneous, Topical

Overview

Brixelle-Shine is a preclinical-stage theranostic nanoparticle developed by Bilix, utilizing the company's BRIXELLE platform. It is composed of PEGylated bilirubin nanoparticles designed to serve a dual purpose: acting as an ultrasound contrast agent for imaging and as a therapeutic agent for inflammatory diseases. The mechanism of action involves the natural ability of bilirubin to scavenge reactive oxygen species (ROS), thereby reducing oxidative stress and inflammation at target sites. As a theranostic, it aims to provide real-time imaging of inflammation while simultaneously delivering anti-inflammatory effects.

Other names: Brixelle-ShinePEGylated bilirubin nanoparticleBRIXELLE-SHINE theranostic

Beyond the preview

Go deeper on Brixelle-Shine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brixelle-Shine.

Explore the full profile